Latest Updates
-
Happy Birthday Dheeraj Dhoopar: How A TV Set Friendship Turned Into Love With Wife Vinny Arora -
Top Skin and Hair Concerns in India in 2025: What the Data Reveals -
International Human Solidarity Day 2025: History, Significance, and Why It Matters -
Purported Video of Muslim Mob Lynching & Hanging Hindu Youth In Bangladesh Shocks Internet -
A Hotel on Wheels: Bihar Rolls Out Its First Luxury Caravan Buses -
Bharti Singh-Haarsh Limbachiyaa Welcome Second Child, Gender: Couple Welcome Their Second Baby, Duo Overjoyed - Report | Bharti Singh Gives Birth To Second Baby Boy | Gender Of Bharti Singh Haarsh Limbachiyaa Second Baby -
Bharti Singh Welcomes Second Son: Joyous News for the Comedian and Her Family -
Gold & Silver Rates Today in India: 22K, 24K, 18K & MCX Prices Fall After Continuous Rally; Check Latest Gold Rates in Chennai, Mumbai, Bangalore, Hyderabad, Ahmedabad & Other Cities on 19 December -
Nick Jonas Dancing to Dhurandhar’s “Shararat” Song Goes Viral -
From Consciousness To Cosmos: Understanding Reality Through The Vedic Lens
Early Metformin Treatment Good For Diabetes

Metformin is an inexpensive, generic drug that helps patients prevent dangerously high blood sugar levels. It will work nearly twice as long, for the people who are taking it within three months of their diabetes diagnosis. To gain the full benefit from metformin, patients should start taking it as soon as they find out they have diabetes. Starting the drug early preserves the body's own ability to control blood sugar, which in turn prevents the long-term complications of diabetes like heart disease, kidney failure, and blindness.
Metformin is recommended as a first-line agent in the treatment of type 2 diabetes, but in most patients it eventually stops working, forcing them to take additional medications to control their blood sugar. Each additional drug adds extra costs and the possibility of more side effects including weight gain. So this study becomes a welcome news for newly diagnosed patients.
This study, named 'The Kaiser Permanente' study, is the first to compare failure rates of metformin in real-world setting. This study has appeared in the March issue of Diabetes Care, a journal of the American Diabetes Association.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications











